{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:28:55Z","timestamp":1791898135390,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Urovant Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40273-022-01163-5","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T04:02:47Z","timestamp":1658808167000},"page":"979-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA"],"prefix":"10.1007","volume":"40","author":[{"given":"Jing Voon","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-5615","authenticated-orcid":false,"given":"Jeffrey","family":"Nesheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul N.","family":"Mudd,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"5","key":"1163_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","volume":"77","author":"KS Coyne","year":"2011","unstructured":"Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081\u20137.","journal-title":"Urology"},{"key":"1163_CR2","doi-asserted-by":"crossref","unstructured":"Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline: American Urological Association; 2019.","DOI":"10.1097\/JU.0000000000000309"},{"issue":"4","key":"1163_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/nau.23477","volume":"37","author":"LC Powell","year":"2018","unstructured":"Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol Urodyn. 2018;37(4):1241\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"1163_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/JOM.0000000000001367","volume":"60","author":"E Durden","year":"2018","unstructured":"Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The direct and indirect costs associated with overactive bladder within a commercially-insured population in the United States. J Occup Environ Med. 2018;60(9):847\u201352.","journal-title":"J Occup Environ Med"},{"issue":"3","key":"1163_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.urology.2009.06.096","volume":"75","author":"ML Ganz","year":"2010","unstructured":"Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526\u201332 (32.e1\u201318).","journal-title":"Urology"},{"issue":"12","key":"1163_CR6","first-page":"CD003193","volume":"12","author":"BP Rai","year":"2012","unstructured":"Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12(12):CD003193.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1163_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"RR Dmochowski","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K, Enemchukwu E, Tee S, Varano S, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40(1):28\u201337.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1163_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026391","volume":"9","author":"SM Szabo","year":"2019","unstructured":"Szabo SM, Gooch K, Schermer C, Walker D, Lozano-Ortega G, Rogula B, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5): e026391.","journal-title":"BMJ Open"},{"key":"1163_CR9","unstructured":"Urovant Sciences, Inc. GEMTESA\u00ae (vibegron). Full Prescribing Information. Irvine, CA: 2020."},{"issue":"2","key":"1163_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"5","key":"1163_CR11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205(5):1421\u20139.","journal-title":"J Urol"},{"issue":"12","key":"1163_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/13696998.2016.1204307","volume":"19","author":"RC Wielage","year":"2016","unstructured":"Wielage RC, Perk S, Campbell NL, Klein TM, Posta LM, Yuran T, et al. Mirabegron for the treatment of overactive bladder: Cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. J Med Econ. 2016;19(12):1135\u201343.","journal-title":"J Med Econ"},{"issue":"2","key":"1163_CR13","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1097\/SPV.0000000000000744","volume":"27","author":"BJ Linder","year":"2021","unstructured":"Linder BJ, Gebhart JB, Elliott DS, Van Houten HK, Sangaralingham LR, Habermann EB. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med Reconstr Surg. 2021;27(2):e261\u20136.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"1163_CR14","unstructured":"US Census Bureau Population Division. Current Population Survey, Annual Social and Economic Supplement. Published March 2019. https:\/\/data.census.gov\/mdat\/#\/. Accessed 6 Apr 2020."},{"issue":"3","key":"1163_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/nau.22295","volume":"32","author":"KS Coyne","year":"2013","unstructured":"Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1163_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/MLR.0000000000000858","volume":"56","author":"AC Kinlaw","year":"2018","unstructured":"Kinlaw AC, Jonsson Funk M, Conover MM, Pate V, Markland AD, Wu JM. Impact of new medications and $4 generic programs on overactive bladder treatment among older adults in the United States, 2000\u20132015. Med Care. 2018;56(2):162\u201370.","journal-title":"Med Care"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urology.2020.04.102","volume":"142","author":"J Jiang","year":"2020","unstructured":"Jiang J, Patil D, Traore EJ, Hammett J, Filson CP. Contemporary patterns of third-line treatments for privately insured individuals with overactive bladder in the United States. Urology. 2020;142:87\u201393.","journal-title":"Urology"},{"issue":"6","key":"1163_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.dmpk.2016.08.002","volume":"31","author":"Y Nomura","year":"2016","unstructured":"Nomura Y, Iitsuka H, Toyoshima J, Kuroishi K, Hatta T, Kaibara A, et al. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females. Drug Metab Pharmacokinet. 2016;31(6):411\u20136.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1163_CR19","unstructured":"Astellas Pharma US Inc. MYRBETRIQ\u00ae (mirabegron extended-release tablets). Full Prescribing Information. Northbrook, IL: 2018."},{"issue":"5","key":"1163_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/pds.3592","volume":"23","author":"S Dechanont","year":"2014","unstructured":"Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions\/visits associated with drug\u2013drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489\u201397.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1163_CR21","unstructured":"Aging Brain Program of the Indiana University Center for Aging Research. Anticholinergic Cognitive Burden Scale 2012 Update. https:\/\/corumpharmacy.com\/wp-content\/uploads\/2020\/08\/Anticholinergic-cognitive-burden-scale.pdf. Accessed 6 Apr 2020."},{"issue":"9","key":"1163_CR22","first-page":"1072","volume":"22","author":"S Perk","year":"2016","unstructured":"Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, et al. Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder. J Manag Care Spec Pharm. 2016;22(9):1072\u201384.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1163_CR23","first-page":"11","volume":"10","author":"A Yehoshua","year":"2018","unstructured":"Yehoshua A, Murray BP, Vasavada SP, Sand PK. Comparing direct medical costs of onabotulinumtoxinA with other common overactive bladder interventions. Am J Pharm Benefits. 2018;10(1):11\u20137.","journal-title":"Am J Pharm Benefits."},{"key":"1163_CR24","unstructured":"US Department of Labor. CPI Inflation Calculator\u2014Medical Care Component (2020) Medical care in U.S. city average, all urban consumers, seasonally adjusted. https:\/\/beta.bls.gov\/dataViewer\/view\/timeseries\/CUSR0000SAM. Accessed 22 June 2020."},{"key":"1163_CR25","unstructured":"Medicare Payment Advisory Commission. March 2020 Report to the Congress: Medicare Payment Policy. Washington, DC: MedPAC; 2020."},{"issue":"4","key":"1163_CR26","first-page":"538","volume":"26","author":"NM Schultz","year":"2020","unstructured":"Schultz NM, O\u2019Day K, Sugarman R, Ramaswamy K. Budget impact of enzalutamide for nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2020;26(4):538\u201349.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"1163_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ijcp.12194","volume":"67","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619\u201332.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"1163_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324\u201333.","journal-title":"Eur Urol"},{"issue":"2","key":"1163_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","volume":"75","author":"HD Mitcheson","year":"2019","unstructured":"Mitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S, et al. Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019;75(2):274\u201382.","journal-title":"Eur Urol"},{"issue":"1","key":"1163_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41669-019-0149-9","volume":"4","author":"H Parise","year":"2020","unstructured":"Parise H, Espinosa R, Dea K, Anaya P, Montoya G, Ng DB. Cost effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in Colombia. Pharmacoecon Open. 2020;4(1):79\u201390.","journal-title":"Pharmacoecon Open."},{"issue":"2","key":"1163_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1464-410X.2009.09073.x","volume":"106","author":"KE Andersson","year":"2010","unstructured":"Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010;106(2):268\u201374.","journal-title":"BJU Int"},{"issue":"4","key":"1163_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","volume":"109","author":"CV Asche","year":"2012","unstructured":"Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 2012;109(4):572\u201380.","journal-title":"BJU Int"},{"issue":"12","key":"1163_CR33","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","volume":"32","author":"ML Ganz","year":"2016","unstructured":"Ganz ML, Liu J, Zou KH, Bhagnani T, Luo X. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016;32(12):1997\u20132005.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1163_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","volume":"59","author":"SD Edmondson","year":"2016","unstructured":"Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, et al. Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609\u201323.","journal-title":"J Med Chem"},{"issue":"12","key":"1163_CR35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","volume":"42","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012;42(12):1187\u201396.","journal-title":"Xenobiotica"},{"issue":"9","key":"1163_CR36","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00345-018-2296-5","volume":"36","author":"PA Leroux","year":"2018","unstructured":"Leroux PA, Brassart E, Lebdai S, Azzouzi AR, Bigot P, Carrouget J. Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder. World J Urol. 2018;36(9):1455\u201360.","journal-title":"World J Urol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01163-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T20:22:25Z","timestamp":1664482945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01163-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"29 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Urovant Sciences (Irvine, CA). Urovant Sciences was involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jing Voon Chen was an employee of Medical Decision Modeling at the time of analysis. James C. Gahn is an employee of Medical Decision Modeling. Jeffrey Nesheim is an employee of Urovant Sciences. Paul N. Mudd,\u00a0Jr. was an employee of Urovant Sciences at the time the work was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Request for data from Urovant Sciences (email: medinfo@urovant.com) will be considered from qualified researchers on a case-by-case basis.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in study conception and design, data collection and analysis, and review and critical revisions of the manuscript and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}